TY - JOUR

T1 - Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ)

T2 - Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

AU - Wannan, Cassandra M.J.

AU - Nelson, Barnaby

AU - Addington, Jean

AU - Allott, Kelly

AU - Anticevic, Alan

AU - Arango, Celso

AU - Baker, Justin T.

AU - Bearden, Carrie E.

AU - Billah, Tashrif

AU - Bouix, Sylvain

AU - Broome, Matthew R.

AU - Buccilli, Kate

AU - Cadenhead, Kristin S.

AU - Calkins, Monica E.

AU - Cannon, Tyrone D.

AU - Cecci, Guillermo

AU - Chen, Eric Yu Hai

AU - Cho, Kang Ik K.

AU - Choi, Jimmy

AU - Clark, Scott R.

AU - Coleman, Michael J.

AU - Conus, Philippe

AU - Corcoran, Cheryl M.

AU - Cornblatt, Barbara A.

AU - Diaz-Caneja, Covadonga M.

AU - Dwyer, Dominic

AU - Ebdrup, Bjørn H.

AU - Ellman, Lauren M.

AU - Fusar-Poli, Paolo

AU - Galindo, Liliana

AU - Gaspar, Pablo A.

AU - Gerber, Carla

AU - Glenthøj, Louise Birkedal

AU - Glynn, Robert

AU - Harms, Michael P.

AU - Horton, Leslie E.

AU - Kahn, René S.

AU - Kambeitz, Joseph

AU - Kambeitz-Ilankovic, Lana

AU - Kane, John M.

AU - Kapur, Tina

AU - Keshavan, Matcheri S.

AU - Kim, Sung Wan

AU - Koutsouleris, Nikolaos

AU - Kubicki, Marek

AU - Kwon, Jun Soo

AU - Langbein, Kerstin

AU - Lewandowski, Kathryn E.

AU - Light, Gregory A.

AU - Mamah, Daniel

AU - Marcy, Patricia J.

AU - Mathalon, Daniel H.

AU - McGorry, Patrick D.

AU - Mittal, Vijay A.

AU - Nordentoft, Merete

AU - Nunez, Angela

AU - Pasternak, Ofer

AU - Pearlson, Godfrey D.

AU - Perez, Jesus

AU - Perkins, Diana O.

AU - Powers, Albert R.

AU - Roalf, David R.

AU - Sabb, Fred W.

AU - Schiffman, Jason

AU - Shah, Jai L.

AU - Smesny, Stefan

AU - Spark, Jessica

AU - Stone, William S.

AU - Strauss, Gregory P.

AU - Tamayo, Zailyn

AU - Torous, John

AU - Upthegrove, Rachel

AU - Vangel, Mark

AU - Verma, Swapna

AU - Wang, Jijun

AU - Rossum, Inge Winter van

AU - Wolf, Daniel H.

AU - Wolff, Phillip

AU - Wood, Stephen J.

AU - Yung, Alison R.

AU - Agurto, Carla

AU - Alvarez-Jimenez, Mario

AU - Amminger, Paul

AU - Armando, Marco

AU - Asgari-Targhi, Ameneh

AU - Cahill, John

AU - Carrión, Ricardo E.

AU - Castro, Eduardo

AU - Cetin-Karayumak, Suheyla

AU - Mallar Chakravarty, M.

AU - Cho, Youngsun T.

AU - Cotter, David

AU - D'Alfonso, Simon

AU - Ennis, Michaela

AU - Fadnavis, Shreyas

AU - Fonteneau, Clara

AU - Gao, Caroline

AU - Gupta, Tina

AU - Gur, Raquel E.

AU - Gur, Ruben C.

AU - Hamilton, Holly K.

AU - Hoftman, Gil D.

AU - Jacobs, Grace R.

AU - Jarcho, Johanna

AU - Ji, Jie Lisa

AU - Kohler, Christian G.

AU - Lalousis, Paris Alexandros

AU - Lavoie, Suzie

AU - Lepage, Martin

AU - Liebenthal, Einat

AU - Mervis, Josh

AU - Murty, Vishnu

AU - Nicholas, Spero C.

AU - Ning, Lipeng

AU - Penzel, Nora

AU - Poldrack, Russell

AU - Polosecki, Pablo

AU - Pratt, Danielle N.

AU - Rabin, Rachel

AU - Rahimi Eichi, Habiballah

AU - Rathi, Yogesh

AU - Reichenberg, Avraham

AU - Reinen, Jenna

AU - Rogers, Jack

AU - Ruiz-Yu, Bernalyn

AU - Scott, Isabelle

AU - Seitz-Holland, Johanna

AU - Srihari, Vinod H.

AU - Srivastava, Agrima

AU - Thompson, Andrew

AU - Turetsky, Bruce I.

AU - Walsh, Barbara C.

AU - Whitford, Thomas

AU - Wigman, Johanna T.W.

AU - Yao, Beier

AU - Yuen, Hok Pan

AU - Ahmed, Uzair

AU - Byun, Andrew Jin Soo

AU - Chung, Yoonho

AU - Do, Kim

AU - Hendricks, Larry

AU - Huynh, Kevin

AU - Jeffries, Clark

AU - Lane, Erlend

AU - Langholm, Carsten

AU - Lin, Eric

AU - Mantua, Valentina

AU - Santorelli, Gennarina

AU - Ruparel, Kosha

AU - Zoupou, Eirini

AU - Adasme, Tatiana

AU - Addamo, Lauren

AU - Adery, Laura

AU - Ali, Munaza

AU - Auther, Andrea

AU - Aversa, Samantha

AU - Baek, Seon Hwa

AU - Bates, Kelly

AU - Bathery, Alyssa

AU - Bayer, Johanna M.M.

AU - Beedham, Rebecca

AU - Bilgrami, Zarina

AU - Birch, Sonia

AU - Bonoldi, Ilaria

AU - Borders, Owen

AU - Borgatti, Renato

AU - Brown, Lisa

AU - Bruna, Alejandro

AU - Carrington, Holly

AU - Castillo-Passi, Rolando I.

AU - Chen, Justine

AU - Cheng, Nicholas

AU - Ching, Ann Ee

AU - Clifford, Chloe

AU - Colton, Beau Luke

AU - Contreras, Pamela

AU - Corral, Sebastián

AU - Damiani, Stefano

AU - Done, Monica

AU - Estradé, Andrés

AU - Etuka, Brandon Asika

AU - Formica, Melanie

AU - Furlan, Rachel

AU - Geljic, Mia

AU - Germano, Carmela

AU - Getachew, Ruth

AU - Goncalves, Mathias

AU - Haidar, Anastasia

AU - Hartmann, Jessica

AU - Jo, Anna

AU - John, Omar

AU - Kerins, Sarah

AU - Kerr, Melissa

AU - Kesselring, Irena

AU - Kim, Honey

AU - Kim, Nicholas

AU - Kinney, Kyle

AU - Krcmar, Marija

AU - Kotler, Elana

AU - Lafanechere, Melanie

AU - Lee, Clarice

AU - Llerena, Joshua

AU - Markiewicz, Christopher

AU - Matnejl, Priya

AU - Maturana, Alejandro

AU - Mavambu, Aissata

AU - Mayol-Troncoso, Rocío

AU - McDonnell, Amelia

AU - McGowan, Alessia

AU - McLaughlin, Danielle

AU - McIlhenny, Rebecca

AU - McQueen, Brittany

AU - Mebrahtu, Yohannes

AU - Mensi, Martina

AU - Hui, Christy Lai Ming

AU - Suen, Yi Nam

AU - Wong, Stephanie Ming Yin

AU - Morrell, Neal

AU - Omar, Mariam

AU - Partridge, Alice

AU - Phassouliotis, Christina

AU - Pichiecchio, Anna

AU - Politi, Pierluigi

AU - Porter, Christian

AU - Provenzani, Umberto

AU - Prunier, Nicholas

AU - Raj, Jasmine

AU - Ray, Susan

AU - Rayner, Victoria

AU - Reyes, Manuel

AU - Reynolds, Kate

AU - Rush, Sage

AU - Salinas, Cesar

AU - Shetty, Jashmina

AU - Snowball, Callum

AU - Tod, Sophie

AU - Turra-Fariña, Gabriel

AU - Valle, Daniela

AU - Veale, Simone

AU - Whitson, Sarah

AU - Wickham, Alana

AU - Youn, Sarah

AU - Zamorano, Francisco

AU - Zavaglia, Elissa

AU - Zinberg, Jamie

AU - Woods, Scott W.

AU - Shenton, Martha E.

N1 - Publisher Copyright: © The Author(s) 2024. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

PY - 2024

Y1 - 2024

N2 - This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

AB - This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

KW - clinical high risk

KW - consortium

KW - early detection

KW - prediction

KW - prevention

KW - psychosis

U2 - 10.1093/schbul/sbae011

DO - 10.1093/schbul/sbae011

M3 - Journal article

C2 - 38451304

AN - SCOPUS:85189877128

VL - 50

SP - 496

EP - 512

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 3

ER -